62 results on '"Hernandez Boluda J"'
Search Results
2. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry
3. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
4. Determinants of early triage for hospitalization in MPN patients with COVID-19
5. Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis
6. Impact of molecular profiling on the management of patients with myelofibrosis
7. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (vol 57, pg 416, 2022)
8. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
9. Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients
10. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
11. How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond
12. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with =2 Tyrosine Kinase Inhibitors
13. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party
14. STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
15. Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation
16. An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation
17. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party (vol 35, pg 2445, 2021)
18. Table 1. Clinical-biological and molecular characteristics of CML patients in each group evaluated
19. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
20. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
21. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review
22. Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant
23. The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
24. DIFFERENT DISEASE BEHAVIOURS AND OUTCOME AFTER AUTOLOGOUS STEM CELLS TRANSPLANT FOR PATIENTS WITH FOLLICULAR LYMPHOMA AND LARGE DIFFUSE B CELLS LYMPHOMA: PH-AB023
25. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia
26. Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide
27. An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients
28. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis
29. Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
30. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide
31. The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey
32. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
33. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis
34. Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes
35. Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
36. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison
37. Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients
38. SUSPENSION OF TREATMENT WITH BCR-ABL INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE WITHIN OF THE CLINICAL ASSISTANCE PRACTICE: SPANISH EXPERIENCE IN A TOTAL OF 236 CASES
39. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
40. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
41. Alleviating anemia and thrombocytopenia in myelofibrosis patients
42. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
43. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method
44. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
45. Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant
46. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
47. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
48. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
49. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
50. Enumeration of cytomegalovirus-specific interferon CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.